Genetic variation in N-acetyltransferase 1 (NAT1) and 2 (NAT2) and risk of non-Hodgkin lymphoma
- PMID: 16847422
- PMCID: PMC1986787
- DOI: 10.1097/01.fpc.0000215071.59836.29
Genetic variation in N-acetyltransferase 1 (NAT1) and 2 (NAT2) and risk of non-Hodgkin lymphoma
Abstract
Animal studies suggest that lymphomagenesis can be induced by exposure to carcinogenic aromatic and heterocyclic amines found in diet, cigarette smoke and the environment, but human epidemiologic investigations of these exogenous exposures have yielded conflicting results. As part of our evaluation of the role of aromatic and heterocyclic amines, which are metabolized by N-acetyltransferase (NAT) enzymes, in the etiology of non-Hodgkin lymphoma (NHL), we examined NHL risk in relation to genetic variation in NAT1 and NAT2 and exposure to cigarette smoke and dietary heterocyclic amines and mutagens. We genotyped 10 common single nucleotide polymorphisms (SNPs) in NAT1 and NAT2 among 1136 cases and 922 controls from a population-based case-control study in four geographical areas of the USA. Relative risk of NHL for NAT1 and NAT2 genotypes, NAT2 acetylation phenotype, and exposure to cigarette smoke and dietary heterocyclic amines and mutagens was estimated using odds ratios (ORs) and 95% confidence intervals (CIs) derived from unconditional logistic regression models. We observed increased risk of NHL among individuals with the NAT1*10/*10 genotype compared with individuals with other NAT1 genotypes (OR = 1.60, 95% CI = 1.04-2.46, P = 0.03). We also observed increased NHL risk in a dose-dependent model among NAT2 intermediate- and rapid-acetylators compared with slow-acetylators, although only the trend was statistically significant (intermediate: OR = 1.18, 95% CI = 0.97-1.44, P = 0.1; rapid: OR = 1.43, 95% CI = 0.97-2.14, P = 0.07; P for linear trend = 0.03). Compared with non-smokers, NHL risk estimates for current cigarette smoking were increased only among NAT2 intermediate/rapid-acetylators (OR = 2.44, 95% CI = 1.15-5.20, P = 0.02). Our data provide evidence that NAT1 and NAT2 genotypes are associated with NHL risk and support a contributory role for carcinogenic aromatic and/or heterocyclic amines in the multi-factorial etiology of NHL.
Similar articles
-
Smoking, variation in N-acetyltransferase 1 (NAT1) and 2 (NAT2), and risk of non-Hodgkin lymphoma: a pooled analysis within the InterLymph consortium.Cancer Causes Control. 2013 Jan;24(1):125-34. doi: 10.1007/s10552-012-0098-4. Epub 2012 Nov 18. Cancer Causes Control. 2013. PMID: 23160945 Free PMC article.
-
Genetic variation in N-acetyltransferases 1 and 2, cigarette smoking, and risk of non-Hodgkin lymphoma.Cancer Causes Control. 2010 Jan;21(1):127-33. doi: 10.1007/s10552-009-9442-8. Epub 2009 Oct 7. Cancer Causes Control. 2010. PMID: 19809881 Free PMC article.
-
Effect of NAT1 and NAT2 genetic polymorphisms on colorectal cancer risk associated with exposure to tobacco smoke and meat consumption.Cancer Epidemiol Biomarkers Prev. 2006 Jan;15(1):99-107. doi: 10.1158/1055-9965.EPI-05-0618. Cancer Epidemiol Biomarkers Prev. 2006. PMID: 16434594
-
Molecular genetics and function of NAT1 and NAT2: role in aromatic amine metabolism and carcinogenesis.Mutat Res. 2002 Sep 30;506-507:65-77. doi: 10.1016/s0027-5107(02)00153-7. Mutat Res. 2002. PMID: 12351146 Review.
-
Joint effects of the N-acetyltransferase 1 and 2 (NAT1 and NAT2) genes and smoking on bladder carcinogenesis: a literature-based systematic HuGE review and evidence synthesis.Am J Epidemiol. 2007 Oct 1;166(7):741-51. doi: 10.1093/aje/kwm167. Epub 2007 Aug 4. Am J Epidemiol. 2007. PMID: 17675654
Cited by
-
Vegetables- and antioxidant-related nutrients, genetic susceptibility, and non-Hodgkin lymphoma risk.Cancer Causes Control. 2008 Jun;19(5):491-503. doi: 10.1007/s10552-008-9111-3. Epub 2008 Jan 17. Cancer Causes Control. 2008. PMID: 18204928 Free PMC article.
-
Genetic variations in xenobiotic metabolic pathway genes, personal hair dye use, and risk of non-Hodgkin lymphoma.Am J Epidemiol. 2009 Nov 15;170(10):1222-30. doi: 10.1093/aje/kwp263. Epub 2009 Oct 12. Am J Epidemiol. 2009. PMID: 19822571 Free PMC article.
-
Functional effects of genetic polymorphisms in the N-acetyltransferase 1 coding and 3' untranslated regions.Birth Defects Res A Clin Mol Teratol. 2011 Feb;91(2):77-84. doi: 10.1002/bdra.20763. Epub 2011 Feb 2. Birth Defects Res A Clin Mol Teratol. 2011. PMID: 21290563 Free PMC article.
-
Phenotype of the most common "slow acetylator" arylamine N-acetyltransferase 1 genetic variant (NAT1*14B) is substrate-dependent.Drug Metab Dispos. 2012 Jan;40(1):198-204. doi: 10.1124/dmd.111.041855. Epub 2011 Oct 18. Drug Metab Dispos. 2012. PMID: 22010219 Free PMC article.
-
NAT1 polymorphisms and cancer risk: a systematic review and meta-analysis.Int J Clin Exp Med. 2015 Jun 15;8(6):9177-91. eCollection 2015. Int J Clin Exp Med. 2015. PMID: 26309576 Free PMC article.
References
-
- Jaffe ES, Harris NL, Stein H, Vardiman JW, editors. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC Press; 2001. World Health Organization Classification of Tumours.
-
- Hartge P, Bracci PM, Wang SS, Devesa SS, Holly EA. Non-Hodgkin lymphoma. In: Schottenfeld D, Fraumeni JF Jr, editors. Cancer Epidemiology and Prevention. Oxford: Oxford Press; 2005.
-
- Sorensen I, Mortensen A, Kristiansen E, van Kreijl C, Adamson R, Thorgeirsson S. Short-term carcinogenicity testing of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) and 2-amino-3-methylimidazo[4,5-f]quinoline (IQ) in E(mu)-pim-1 transgenic mice. Carcinogenesis. 1996;17:2221–2227. - PubMed
-
- National Toxicology Program. Bioassay of 2,4-diaminotoluene for possible carcinogenicity. Natl Cancer Inst Carcinog Tech Rep Ser. 1979;162:1–139. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials